• Something wrong with this record ?

Asthma in the era of COVID-19

S. Assaf, H. Stenberg, M. Jesenak, SP. Tarasevych, NA. Hanania, Z. Diamant

. 2023 ; 218 (-) : 107373. [pub] 20230810

Language English Country England, Great Britain

Document type Review, Journal Article

Persistent link   https://www.medvik.cz/link/bmc24000889

Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000889
003      
CZ-PrNML
005      
20240213093439.0
007      
ta
008      
240109e20230810enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.rmed.2023.107373 $2 doi
035    __
$a (PubMed)37567514
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Assaf, Sara $u Section of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, NM, USA. Electronic address: SAssaf@salud.unm.edu
245    10
$a Asthma in the era of COVID-19 / $c S. Assaf, H. Stenberg, M. Jesenak, SP. Tarasevych, NA. Hanania, Z. Diamant
520    9_
$a Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management.
650    _2
$a lidé $7 D006801
650    12
$a COVID-19 $x epidemiologie $x komplikace $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    12
$a bronchiální astma $x diagnóza $7 D001249
650    _2
$a komorbidita $7 D015897
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
655    _2
$a přehledy $7 D016454
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stenberg, Henning $u Center for Primary Health Care Research, Lund University, Malmö, Sweden
700    1_
$a Jesenak, Milos $u Departments of Pulmonology and Phthisiology and Paediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovak Republic
700    1_
$a Tarasevych, Svitlana P $u Department of Respiratory Medicine, Zaans Medical Center, Zaandam, the Netherlands
700    1_
$a Hanania, Nicola A $u Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA
700    1_
$a Diamant, Zuzana $u Dept of Microbiology Immunology & Transplantation, KU Leuven, Catholic University of Leuven, Belgium; Dept of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; Dept Clin Pharm & Pharmacol, Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. Electronic address: z.diamant@4gems.nl
773    0_
$w MED00004105 $t Respiratory medicine $x 1532-3064 $g Roč. 218 (20230810), s. 107373
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37567514 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093436 $b ABA008
999    __
$a ok $b bmc $g 2049481 $s 1210583
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 218 $c - $d 107373 $e 20230810 $i 1532-3064 $m Respiratory medicine $n Respir Med $x MED00004105
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options